-+ 0.00%
-+ 0.00%
-+ 0.00%

Neumora: Can Restarted Trials Justify Cash Runway Through Mid-Year Only?

Barchart·08/04/2026 16:23:35
語音播報
Barchart +13.16% Beat Sep 2025 $-0.34 $-0.35 -2.94% Miss Dec 2025 $-0.34 $-0.35 -2.94% Miss Mar 2026 $-0.32 $-0.30 +6.25% Beat

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

NMRA's earnings timing is not specified in the available data, but historical price action provides insight into typical post-earnings volatility patterns.

Earnings Date Day 0 Move Day 0 Range Day +1 Move Day +1 Range
2026-05-07 -$0.39 (-16.74%) $0.47 (20.17%) -$0.11 (-5.67%) $0.23 (11.60%)
2026-03-30 -$0.40 (-17.17%) $0.33 (14.25%) +$0.02 (+1.04%) $0.15 (7.51%)
2025-11-06 -$0.04 (-1.53%) $0.41 (15.50%) -$0.02 (-0.78%) $0.23 (9.11%)
2025-08-06 -$0.07 (-4.22%) $0.12 (7.23%) +$0.06 (+3.77%) $0.11 (6.89%)
2025-05-12 +$0.03 (+4.47%) $0.10 (14.84%) -$0.01 (-1.89%) $0.09 (13.23%)
2025-03-03 -$0.16 (-9.94%) $0.23 (14.74%) +$0.00 (+0.36%) $0.15 (10.68%)
2024-11-12 -$2.33 (-17.08%) $2.19 (16.06%) -$0.54 (-4.73%) $0.97 (8.62%)
2024-08-06 +$0.03 (+0.25%) $0.51 (4.26%) -$0.20 (-1.67%) $0.50 (4.17%)
Avg Abs Move 8.92% 13.38% 2.49% 8.98%

NMRA exhibits significant volatility around earnings releases, with an average absolute Day 0 move of 8.92% and Day +1 move of 2.49%. The Day 0 range averages 13.38%, indicating substantial intraday swings as investors digest results.

The most dramatic reaction came in November 2024, when shares plunged 17.08% on Day 0 with a 16.06% intraday range, followed by an additional 4.73% decline on Day +1. More recently, the May 2026 earnings triggered a 16.74% Day 0 decline despite the company beating estimates, suggesting investors were disappointed by guidance or other qualitative factors.

The pattern shows directional inconsistency—some quarters see sharp declines while others produce modest gains—but the magnitude of moves is consistently elevated. The 13.38% average Day 0 range indicates that regardless of direction, investors should expect substantial price swings. The Day +1 follow-through (averaging 2.49%) suggests initial reactions tend to moderate somewhat in the subsequent session, though not always in a favorable direction.

Part 2.2: Options Market Expected Move

Metric Value
Expiration Date 08/21/26 (DTE 17)
Expected Move $0.1105 (6.91%)
Expected Range $1.4895 to $1.7105
Implied Volatility 213.86%

The options market is pricing a 6.91% expected move through the August 21 expiration (17 days post-earnings), which is notably lower than NMRA's historical average Day 0 move of 8.92%. This suggests options traders may be underpricing near-term volatility, or alternatively, that recent price action has reduced expectations for dramatic post-earnings swings compared to the company's historical pattern.

Part 3: What Analysts Are Saying

Analysts maintain a cautiously optimistic stance on NMRA with an average recommendation of 4.00 (Buy) based on 10 ratings. The breakdown shows 5 Strong Buys, 2 Moderate Buys, 2 Holds, and 1 Strong Sell, reflecting a consensus that favors accumulation despite the company's pre-revenue status and ongoing losses.

The average price target of $6.14 implies 284% upside from the current price of $1.60, with estimates ranging from a low of $3.00 to a high of $14.00. This wide range reflects significant uncertainty about the company's ultimate commercial potential, with bulls seeing substantial value in the pipeline while bears remain concerned about execution risk and capital requirements.

Analyst sentiment has remained unchanged over the past month, with no shifts in the rating distribution or average recommendation. This stability suggests the analyst community is in a wait-and-see mode heading into earnings, likely looking for concrete updates on clinical progress and cash management before adjusting their views. The substantial gap between the current price and consensus target indicates analysts believe the market is overly discounting NMRA's prospects, though the presence of a Strong Sell rating and the stock's technical weakness suggest not all market participants share this optimism.

Part 4: Technical Picture

NMRA enters earnings with deteriorating technical momentum across all timeframes. The Barchart Technical Opinion currently stands at 100% Sell, strengthening from 72% Sell one week ago and 72% Sell one month ago. This intensification of selling pressure reflects growing bearish conviction as the stock approaches its earnings release.

Timeframe Analysis:

  • Short-term (100% Sell): Strong sell signal indicates immediate downward pressure and negative near-term momentum heading into the earnings event
  • Medium-term (100% Sell): Sell signal confirms weakness extends beyond just recent sessions, suggesting an established intermediate-term downtrend
  • Long-term (100% Sell): Strong sell signal reflects persistent weakness in the longer-term trend, with the stock failing to establish any sustainable upward momentum

Trend Characteristics: The signal strength is rated as Good with direction characterized as Strongest, indicating high confidence in the bearish trend and suggesting the downward momentum is well-established and persistent.

Period Value Period Value
5-Day MA $1.6300 50-Day MA $1.6412
10-Day MA $1.6080 100-Day MA $1.9271
20-Day MA $1.6133 200-Day MA $2.1739

The stock is trading below all major moving averages, a technically bearish configuration that underscores the weakness in the trend structure. NMRA sits below its 5-day ($1.63), 10-day ($1.61), 20-day ($1.61), 50-day ($1.64), 100-day ($1.93), and 200-day ($2.17) moving averages, with the distance from longer-term averages particularly pronounced—the stock is 26% below its 200-day MA. This alignment of moving averages in descending order confirms a well-defined downtrend across all timeframes. The technical setup heading into earnings is decidedly cautionary, with no support levels nearby and momentum indicators uniformly negative. Any disappointment in the earnings report or guidance could trigger further downside, while a positive surprise would need to be substantial to overcome the entrenched bearish technical picture and trigger a meaningful reversal.

This article was generated using Barchart’s automated content technology and existing data APIs. As a result, we are able to provide readers with timely, actionable, in-depth analysis on more equities, allowing them to make more informed decisions. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here. And, if you would like to report any inaccuracies, please contact news@barchart.com.